Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Guaraldi

Showing results (341-350 of 408) with videos related to

Pageof 41
Sort By:
International Urology and Nephrology|June 11, 2021
Acid base disorders in patients with COVID-19Gaetano Alfano, Francesco Fontana, Giacomo Mori, et al.
The Journal of Antimicrobial Chemotherapy|June 13, 2021
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIVAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
Frontiers in Aging|November 24, 2025
Correction: Health profiles of foreign-born elderly women with HIV in ItalyStefania Arsuffi, Eugenia Quiros-Roldan, Fabio Riccardo Colombo, et al.
European Journal of Immunology|December 6, 2021
Metabolic reprograming shapes neutrophil functions in severe COVID-19Rebecca Borella, Sara De Biasi, Annamaria Paolini, et al.
Open Forum Infectious Diseases|February 11, 2022
Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID SyndromeJovana Milic, Sara Barbieri, Licia Gozzi, et al.
AIDS (London, England)|February 19, 2005
CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/lCristina Mussini, Andrea Bedini, Vanni Borghi, et al.
The Journal of Antimicrobial Chemotherapy|August 4, 2023
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravirAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
Hepatology (Baltimore, Md.)|May 1, 2026
FIB-4 fails to identify significant liver fibrosis in people with HIV: A large multinational screening studyFelice Cinque, Sahar Saeed, Francesca Farina, et al.
HIV Medicine|October 18, 2023
Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023Juan Ambrosioni, Laura Levi, Jasmini Alagaratnam, et al.
American Journal of Preventive Cardiology|April 20, 2026
A machine learning-derived cardiovascular risk score in people with HIV: the ML-ICONA scoreOvidio De Filippo, Francesco Codicè, Alessandro Tavelli, et al.
Pageof 41

Showing results (341-350 of 408) with videos related to

Sort By:
Pageof 41
International Urology and Nephrology|June 11, 2021
Acid base disorders in patients with COVID-19Gaetano Alfano, Francesco Fontana, Giacomo Mori, et al.
The Journal of Antimicrobial Chemotherapy|June 13, 2021
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIVAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
Frontiers in Aging|November 24, 2025
Correction: Health profiles of foreign-born elderly women with HIV in ItalyStefania Arsuffi, Eugenia Quiros-Roldan, Fabio Riccardo Colombo, et al.
European Journal of Immunology|December 6, 2021
Metabolic reprograming shapes neutrophil functions in severe COVID-19Rebecca Borella, Sara De Biasi, Annamaria Paolini, et al.
Open Forum Infectious Diseases|February 11, 2022
Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID SyndromeJovana Milic, Sara Barbieri, Licia Gozzi, et al.
AIDS (London, England)|February 19, 2005
CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/lCristina Mussini, Andrea Bedini, Vanni Borghi, et al.
The Journal of Antimicrobial Chemotherapy|August 4, 2023
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravirAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
Hepatology (Baltimore, Md.)|May 1, 2026
FIB-4 fails to identify significant liver fibrosis in people with HIV: A large multinational screening studyFelice Cinque, Sahar Saeed, Francesca Farina, et al.
HIV Medicine|October 18, 2023
Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023Juan Ambrosioni, Laura Levi, Jasmini Alagaratnam, et al.
American Journal of Preventive Cardiology|April 20, 2026
A machine learning-derived cardiovascular risk score in people with HIV: the ML-ICONA scoreOvidio De Filippo, Francesco Codicè, Alessandro Tavelli, et al.
Pageof 41